CASK on XNAS, Wholesale Trade, Sempreon, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue fell 16% to $487M over 12 months and losses reached $250.5M.
BadLatest quarter revenue fell 9.9% from a year earlier
BadDebt of $341.2M against just $13.6M of cash
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Sempreon Inc is a producer and supplier of distilled spirits, specialty wheat protein, and starch food ingredients based in the United States. It operates in three reportable segments: Distillery Solutions, Branded Spirits Segment, and Ingredient Solutions. Maximum revenue is generated from the Branded Spirits segment, which consists of a portfolio of brands that it produces through its distilleries and bottling facilities and sells to distributors or to state governments that directly control the sale of alcohol. MGP's branded spirits include various brands across numerous categories and price tiers, such as Penelope Bourbon, Yellowstone Bourbon, Minor Case Straight Rye Whiskey, Brady's Irish Cream, Exotico Tequila, Arrow Cordials, Canada House Canadian Whisky, Lady Bligh Rum, etc.
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $117.9M, net income $6.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $214.9M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$117.9M
$6.9M
30 Jun 2026
$124.4M
$12.0M
31 Mar 2026
$106.4M
-$134.8M
31 Dec 2025
$138.3M
-$134.6M
30 Sep 2025
$130.9M
$15.4M
30 Jun 2025
$145.5M
$14.4M
31 Mar 2025
$121.7M
-$3.0M
31 Dec 2024
$180.8M
-$42.0M
30 Sep 2024
$161.5M
$23.9M
30 Jun 2024
$190.8M
$32.1M
31 Mar 2024
$170.6M
$20.6M
31 Dec 2023
$214.9M
$31.1M
30 Sep 2023
$211.6M
$13.2M
30 Jun 2023
$209.0M
$32.1M
31 Mar 2023
$201.0M
$31.1M
31 Dec 2022
$191.0M
$22.5M
30 Sep 2022
$201.1M
$23.8M
30 Jun 2022
$195.0M
$25.6M
31 Mar 2022
$195.2M
$37.4M
31 Dec 2021
$166.8M
$31.7M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$487.0M
$578.9M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-16%
+6.7%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$250.5M
-$15.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$11.66
-$0.63
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
34.7%
39.0%
20.9%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-57.2%
1.8%
3.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-51.4%
-2.6%
1.3%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-34.5%
7.9%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$527K
$62.2M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$13.6M
$13.4M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$341.2M
$268.7M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$327.6M
$255.3M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.57
0.59
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$27.87
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
18.8
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
0.74
0.64
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
1.4
0.77
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.60
1.9
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
2.9%
1.4%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$2.1M
bought $0, sold $2.1M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
–
No data for this company
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
29.0M shares held by 13F filers (30 Sep 2026) of 21.4M outstanding (23 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
No FINRA short interest report in the last 60 days.
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
–
No FINRA short interest report in the last 60 days.
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
–
No FINRA short interest report in the last 60 days.
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
51%
51% of off-exchange volume on 20 Nov 2026 was short sales
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-9.9%
$117.9M vs $130.9M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-45%
$4.7M vs $8.5M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$30K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
3
3 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
3 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $16.83 on 20 Nov 2026, +2705% over 12 months (12-month range $16.83 to $18.55)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $10.7M in the last 12 months (the 12 months before: -$18.0M).Revenue per quarter. Revenue $117.9M in the latest quarter, -9.9% on a year earlier.Capital spending per quarter. Capital spending $4.7M in the latest quarter, -45% on a year earlier.Institutional holders (13F filers). 139 13F filers reported holding it in the latest 13F quarter, 0% on a year earlier.Lobbying spend. Lobbying spend: $30K published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $166.8M, +65% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $195.2M, +80% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $195.0M, +11% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $201.1M, +14% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $191.0M, +14% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $201.0M, +3.0% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $209.0M, +7.2% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $211.6M, +5.2% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $214.9M, +13% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $170.6M, -15% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $190.8M, -8.7% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $161.5M, -24% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $180.8M, -16% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $121.7M, -29% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $145.5M, -24% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $130.9M, -19% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $138.3M, -23% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $106.4M, -13% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $124.4M, -15% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $117.9M, -9.9% on a year earlier; public on 29 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $10.1M, +64% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $10.6M, -12% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $7.4M, +19% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $11.1M, -41% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $16.1M, +59% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $16.2M, +53% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $13.8M, +86% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $12.0M, +7.9% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $13.2M, -18% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $27.0M, +66% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $6.4M, -54% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $19.5M, +62% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $18.3M, +39% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $19.9M, -26% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $12.2M, +92% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $8.5M, -56% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $4.8M, -74% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $5.7M, -71% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $4.5M, -63% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $4.7M, -45% on a year earlier; public on 29 Oct 2026
Institutional holders (13F filers)
30 Sep 2026 report: 139; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jul 2026: $30K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is short interest, shares (FINRA, settlement date; published ~7 business days later) at 3.4M (15 Sep 2025), 23× its normal reading; higher than 100% of its own history.
Reported lobbying spend: $30K in Q2 2026, $20K in Q1 2019. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Seeking federal funding to assist with bio-based polymer development and product commercialization; with focus on Department of Agriculture, SBA. Also monitor treatment of key program budgets in FY 2013 CR and FY 2014 House and Senate appropriations.; Monitoring agriculture reauthorization legislation; with focus on R&D for biobased products and other programs important to client interests.Budget, Agriculture
Working with client to assist with funding for biobased polymer research, development and commercialization. Also assisting with federal marketing of biobased products.Government issues, Agriculture, Budget
Two or more unrelated kinds of records unusual within 30 days
4 Dec 2021confirmed
Confirmed across sources Insiders and Filings + Financials
Sempreon(CASK): spent $18.9M on capital projects in the quarter ended 30 Sep 2021, 5.7× the same quarter last year, while it had 3 insiders buy $1.8M of its shares on the open market within 30 days (3 filings). Two unrelated kinds of activity within 24 days.
Financials: Quarterly capital spending jump, became public on 9 Nov 2021
Financials: Quarterly revenue change, became public on 9 Nov 2021
Insiders: Clustered insider buying, became public on 4 Dec 2021
The quarter ended 30 Sep 2021 against the 8 quarters before it.
this quarterearliernormal: $5.9MSee the evidence (3 changes)
Financials: Quarterly capital spending jump became public on 9 Nov 2021
Sempreon spent $18.9M on capital projects in the quarter ended 30 Sep 2021, 5.7× the same quarter last year.
This period
$18.9M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$5.9M
Typical spread (median absolute deviation)
$912K
How far from its usual level
+9.6
Same quarter last year
$3.3M
History used
4,018 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $5.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 9 Nov 2021
Sempreon reported revenue of $176.6M for the quarter ended 30 Sep 2021, 1.7× the same quarter last year.
This period
$176.6M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$100.0M
Typical spread (median absolute deviation)
$7.5M
How far from its usual level
+6.9
Same quarter last year
$103.0M
History used
4,018 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $100.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
20 Jul 2026Lobbying change
lobbying on a new issue.
See the evidence
New
['TAX']
Rule
only points whose every posting (and value revision) is at or before as_of
reported revenue of $121.7M for the quarter ended 31 Mar 2025, 29% below the same quarter last year.
Same quarter last year: $170.6M; its normal quarter is $195.9M.
See the evidence
This period
$121.7M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$195.9M
Typical spread (median absolute deviation)
$15.4M
How far from its usual level
-3.2
Same quarter last year
$170.6M
History used
5,296 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $195.9M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
spent $27.0M on capital projects in the quarter ended 31 Mar 2024, 1.7× the same quarter last year.
Same quarter last year: $16.2M; its normal quarter is $12.6M.
See the evidence
This period
$27.0M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$12.6M
Typical spread (median absolute deviation)
$1.7M
How far from its usual level
+5.7
Same quarter last year
$16.2M
History used
4,931 days
the quarter ended 31 Mar 20248 earlier quartersnormal: $12.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
reported revenue of $195.2M for the quarter ended 31 Mar 2022, 1.8× the same quarter last year.
Same quarter last year: $108.3M; its normal quarter is $105.6M.
See the evidence
This period
$195.2M (the quarter ended 31 Mar 2022)
Normal quarter (median of 8 earlier)
$105.6M
Typical spread (median absolute deviation)
$9.8M
How far from its usual level
+6.2
Same quarter last year
$108.3M
History used
4,200 days
the quarter ended 31 Mar 20228 earlier quartersnormal: $105.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 103 entries; narrow the window or the kind of data to see older ones.
Not listed: 354 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000835011
Ticker
CASK
Domain
sempreon.com
Hq location
KS|ATCHISON|66002 (1 unverified)
Lobbying client
mgp ingredients
Name
Luxco, Inc, MGP INGREDIENTS INC, MGPI of Indiana, LLC, MGPI Processing, Inc and 2 more
Federal lobbying disclosures (LDA)6 records, 103 data points1 Dec 2004 to 30 Sep 2026
SEC Form 13F institutional holdings9 data points30 Sep 2026 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)150 records10 Mar 2016 to 28 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1049 data points30 Jun 2008 to 23 Oct 2026
SEC Form 4 insider transactions277 records, 788 data points16 Mar 2016 to 12 Nov 2026
FINRA short interest (twice monthly)59 data points29 Nov 2024 to 15 Sep 2025
FINRA daily short sale volume (off-exchange)440 data points22 Nov 2024 to 20 Nov 2026